🇺🇸 Sodium Ozagrel in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 15

Most-reported reactions

1. Cerebral Infarction — 3 reports (20%)
2. Anaphylactic Shock — 2 reports (13.33%)
3. Chest Pain — 2 reports (13.33%)
4. Vision Blurred — 2 reports (13.33%)
5. Abdominal Pain Lower — 1 report (6.67%)
6. Artery Dissection — 1 report (6.67%)
7. Arthralgia — 1 report (6.67%)
8. Back Pain — 1 report (6.67%)
9. Blood Pressure Decreased — 1 report (6.67%)
10. Blood Pressure Fluctuation — 1 report (6.67%)

Source database →

Frequently asked questions

Is Sodium Ozagrel approved in United States?

Sodium Ozagrel does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Sodium Ozagrel in United States?

Tanabe Pharma Corporation is the originator. The local marketing authorisation holder may differ — check the official source linked above.